Saad Usmani, MD, FACP, Division Chief of Plasma Cell Disorders and Director of Clinical Research in Hematological Malignancies at Levine Cancer Institute, discusses potential future uses of cilta-cel, an investigational treatment for relapsed/refractory multiple myeloma.
Multiple myeloma is a blood cancer associated with uncontrolled growth of plasma cells. Abnormal plasma cells – also known as myeloma cells – interfere with the production of healthy blood cells in the bone marrow. Myeloma cells also produce inactive clones of abnormal antibodies that may negatively affect the bones and kidneys. Symptoms of multiple myeloma may include: bone pain (particularly in the chest and spine), frequent infections, weakness or numbness in the legs, fatigue, confusion, excessive thirst, and constipation. While the disease is treatable, relapses are common and some patients are refractory to first line treatment.
As Dr. Usmani explains, cilta-cel is being investigated in multiple clinical trials including CARTITUDE-2 study and the CARTITUDE-4 study that involve varying patient cohorts. Cilta-cel is currently under investigation by the FDA based on data from the CARTITUDE-1 study involving patients with relapsed/refractory multiple myeloma. An approval decision is expected by November 29, 2021. According to Dr. Usmani, the other trials will hopefully lead to the use of cilta-cel as an earlier line of therapy for multiple myeloma.
To learn more about multiple myeloma, visit our Multiple Myeloma Learning Page.